Cohera Medical Awarded Phase II SBIR Grant for Continued Development

Tag : Plastic Product Development
Cohera Medical Inc. todayannounced that it has been selected to receive a Phase II SmallBusiness Innovation Research (SBIR) grant of $1.5 million for theongoing development of TissuGlu, a novel surgical adhesive forapplication in plastic surgery.
The Phase II SBIR grant, awarded by the National Institutes ofHealth (NIH), will fund work to finalize the pre-clinical testingthat will support submission of an Investigational Device Exemption(IDE) to the Food and Drug Administration (FDA) for approval toinitiate human clinical trials. In the second year of the award,human clinical trials will be initiated to establish the product'ssafety and efficacy.
"Cohera is honored to receive this prestigious and selective awardin the current highly competitive environment," said Patrick Daly,president and CEO of Cohera Medical. "Through this award, the NIHacknowledges the innovative nature of Cohera's technology as wellas the robust commercial potential of TissuGlu. Our ongoing plansfor TissuGlu seek to establish its safety and efficacy as asurgical adhesive to reduce fluid accumulation and the need fordrains after surgery. The grant follows the successful completionof the Phase I SBIR project, which established the efficacy of theproduct formulation and the dispenser device design in preliminarystudies."
About Cohera Medical
Cohera Medical Inc. is a Pittsburgh-based company that isdeveloping a revolutionary line of wound management products andsurgical adhesives. Cohera Medical's products are based on a uniquechemical design that is purely synthetic, easy to use,biocompatible and fully resorbable. The company's lead product indevelopment, TissuGlu, is a sprayable bonding agent for plasticsurgery procedures. TissuGlu adheres flaps of tissue after surgicalprocedures, eliminating the spaces where fluid accumulates andreducing wound drainage. Cohera Medical is also developing surgicaladhesives targeting mesh fixation and small bone fixation, whichwill fill similar market needs in both orthopedics and generalsurgery. For more information, visit www.coheramed.com . TissuGlu and the other Cohera products have not yet been approvedfor medical use by the Food and Drug Administration (FDA) in theU.S. or by any other country's regulatory authority.
Certain statements made throughout this press release that are nothistorical facts contain forward-looking statements regarding theCompany's future plans, objectives and expected performance. Anysuch forward-looking statements are based on assumptions that theCompany believes are reasonable, but are subject to a wide range ofrisks and uncertainties and, therefore, there can be no assurancethat actual results may not differ materially from those expressedor implied by such forward-looking statements.